Journal article
Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy
Abstract
Aim: To examine neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in prognosticating immunotherapy efficacy. Methods: A retrospective study of 156 patients with metastatic melanoma and non-small-cell lung cancer on PD-1 inhibitors. Results: Baseline NLR ≥5 was associated with worse progression-free survival (hazard ratio [HR]: 1.53; 95% CI: 1.01-2.31; p = 0.043) but nonsignificant worse overall survival trend (HR: 1.51;…
Authors
Kartolo A; Holstead R; Khalid S; Emack J; Hopman W; Robinson A; Baetz T
Journal
Immunotherapy, Vol. 12, No. 11, pp. 785–798
Publisher
Taylor & Francis
Publication Date
August 2020
DOI
10.2217/imt-2020-0105
ISSN
1750-743X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAged, 80 and overBiomarkers, PharmacologicalBlood PlateletsCarcinoma, Non-Small-Cell LungCell CountFemaleHumansImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsLymphocytesMaleMelanomaNeoplasm MetastasisNeutrophilsPrognosisProgrammed Cell Death 1 ReceptorRetrospective StudiesSkin NeoplasmsSurvival Analysis